Monte Rosa reports Phase 1 data for MRT-8102 in cardiovascular risk studyOct 1Clinical readoutMonte Rosa Therapeutics, Inc
ADARx prices IPO at $17 per share, AbbVie to buy stakeSep 25FinancingAbbVieADARx Pharmaceuticals, Inc.
Black Hawk discloses missed trust deposits amid pending Vesicor mergerSep 21FinancingBlack Hawk Acquisition Corp
Novartis's pelacarsen fails cardiovascular outcomes trial in Phase 3 studySep 4Clinical readoutIonis PharmaceuticalsNovartis
ADARx Pharmaceuticals files S-1 for Nasdaq IPO under ticker ADRXSep 4FinancingADARx Pharmaceuticals, Inc.inclisiran sodium
Scribe Therapeutics starts Phase 1 trial of PCSK9 silencer STX-1150, completes upsized IPOSep 2Quarterly updateScribe Therapeutics, Inc.
AbCellera completes pricing of $200 million offering, files final prospectus supplementAug 13FinancingAbCellera Biologics Inc.
Silexion prices $2.5 million public offering, closes it days laterAug 13FinancingSilexion Therapeutics Corp
NewAmsterdam reports positive CHMP opinion for obicetrapib, sets PREVAIL and RUBENS timelinesAug 5Quarterly updateNewAmsterdam Pharma Co N.V.
Editas reports Q2 2026 results, plans Australia CTN filing for EDIT-401Aug 5Quarterly updateEditas Medicine, Inc.
BNB Plus faces Nasdaq delisting determination, moves to OTCQB pending appealAug 5FinancingApplied Dna Sciences INC
Amgen updates MariTide pipeline, discontinues AMG 513, keeps pressing FDA on TAVNEOSAug 4Quarterly updateAMG-513Amgen
CRISPR Therapeutics reports Q2 2026 results, expanded CASGEVY approval and new trial startsAug 3Quarterly updateCRISPR Therapeutics AGCTX340
Madrigal advances MGL-2086 into Phase 1, adds resmetirom patents, posts Q2 2026 resultsJul 30Quarterly updateMadrigal Pharmaceuticals, Inc.resmetirom
LB Pharmaceuticals sets $150 million private placement of stock and warrantsJul 29FinancingLB Pharmaceuticals Inc.LB-102
Ionis posts Q2 2026 results, flags second-half pipeline milestonesJul 29Quarterly updatedonidalorsenIonis Pharmaceuticals
NewAmsterdam and Menarini get positive EU CHMP opinion for obicetrapib medicinesJul 24Regulatory milestoneNewAmsterdam Pharma Co N.V.
Scribe Therapeutics prices $128.7 million IPO at $15 per shareJul 24FinancingScribe Therapeutics, Inc.
Latigo Biotherapeutics files for IPO on Nasdaq under ticker LTGOJul 17FinancingLatigo Biotherapeutics
Novartis posts pelacarsen Phase 3 apheresis results, updates three drug labelsJul 17Weekly roundup, 8 itemscarbamazepineimatinib
MeiraGTx secures up to $400 million from Oberland Capital for gene therapy programsJul 7Regulatory decisionMeiraGTx, LLC
Scribe Therapeutics files S-1 for Nasdaq IPO under ticker SCTXJul 2FinancingScribe Therapeutics, Inc.
Sign inSign in